{"id":"https://openalex.org/W3093071830","doi":"https://doi.org/10.3390/pharmaceutics12100986","title":"Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer","display_name":"Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer","alternate_titles":[],"publication_year":2020,"publication_date":"2020-10-19","ids":{"openalex":"https://openalex.org/W3093071830","doi":"https://doi.org/10.3390/pharmaceutics12100986","mag":"3093071830","pmid":"https://pubmed.ncbi.nlm.nih.gov/33086530","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7589709"},"language":"en","primary_location":{"id":"doi:10.3390/pharmaceutics12100986","doi":"https://doi.org/10.3390/pharmaceutics12100986","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics12100986","pdf_url":"https://www.mdpi.com/1999-4923/12/10/986/pdf?version=1603097897","source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3093071830"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.mdpi.com/1999-4923/12/10/986/pdf?version=1603097897","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008523687","display_name":"Francisco J. Cimas","orcid":"https://orcid.org/0000-0001-9241-331X","observed_orcids":["https://orcid.org/0000-0001-9241-331X"]},"institutions":[{"id":"https://openalex.org/I4210155114","display_name":"Complejo Hospitalario Universitario de Albacete","ror":"https://ror.org/04a5hr295","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210141158","https://openalex.org/I4210155114"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/writing-original-draft","display_name":"Writing \u2013 original draft"}],"raw_author_name":"Francisco J. Cimas","raw_affiliation_strings":["Oncolog\u00eda Traslacional, Centro Regional de Investigaciones Biom\u00e9dicas, 02008 Albacete, Spain","Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncolog\u00eda Traslacional, Centro Regional de Investigaciones Biom\u00e9dicas, 02008 Albacete, Spain","institution_ids":[]},{"raw_affiliation_string":"Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain","institution_ids":["https://openalex.org/I4210155114"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062035433","display_name":"Enrique Niza","orcid":"https://orcid.org/0000-0003-2845-4509","observed_orcids":["https://orcid.org/0000-0003-2845-4509"]},"institutions":[{"id":"https://openalex.org/I79189158","display_name":"University of Castilla-La Mancha","ror":"https://ror.org/05r78ng12","country_code":"ES","type":"education","lineage":["https://openalex.org/I79189158"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"}],"raw_author_name":"Enrique Niza","raw_affiliation_strings":["Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain"],"raw_orcid":"https://orcid.org/0000-0003-2845-4509","affiliations":[{"raw_affiliation_string":"Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","institution_ids":[]},{"raw_affiliation_string":"Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain","institution_ids":["https://openalex.org/I79189158"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059183690","display_name":"Alberto Juan","orcid":"https://orcid.org/0000-0002-4159-9772","observed_orcids":["https://orcid.org/0000-0002-4159-9772"]},"institutions":[{"id":"https://openalex.org/I4210155114","display_name":"Complejo Hospitalario Universitario de Albacete","ror":"https://ror.org/04a5hr295","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210141158","https://openalex.org/I4210155114"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/writing-original-draft","display_name":"Writing \u2013 original draft"}],"raw_author_name":"Alberto Juan","raw_affiliation_strings":["Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain"],"raw_orcid":"https://orcid.org/0000-0002-4159-9772","affiliations":[{"raw_affiliation_string":"Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","institution_ids":[]},{"raw_affiliation_string":"Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain","institution_ids":["https://openalex.org/I4210155114"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025585029","display_name":"Mar\u00eda del Mar Noblejas\u2010L\u00f3pez","orcid":"https://orcid.org/0000-0001-9250-9688","observed_orcids":["https://orcid.org/0000-0001-9250-9688"]},"institutions":[{"id":"https://openalex.org/I4210155114","display_name":"Complejo Hospitalario Universitario de Albacete","ror":"https://ror.org/04a5hr295","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210141158","https://openalex.org/I4210155114"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"}],"raw_author_name":"Mar\u00eda del Mar Noblejas-L\u00f3pez","raw_affiliation_strings":["Oncolog\u00eda Traslacional, Centro Regional de Investigaciones Biom\u00e9dicas, 02008 Albacete, Spain","Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain"],"raw_orcid":"https://orcid.org/0000-0001-9250-9688","affiliations":[{"raw_affiliation_string":"Oncolog\u00eda Traslacional, Centro Regional de Investigaciones Biom\u00e9dicas, 02008 Albacete, Spain","institution_ids":[]},{"raw_affiliation_string":"Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain","institution_ids":["https://openalex.org/I4210155114"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041924075","display_name":"Iv\u00e1n Bravo","orcid":"https://orcid.org/0000-0003-1589-5399","observed_orcids":["https://orcid.org/0000-0003-1589-5399"]},"institutions":[{"id":"https://openalex.org/I79189158","display_name":"University of Castilla-La Mancha","ror":"https://ror.org/05r78ng12","country_code":"ES","type":"education","lineage":["https://openalex.org/I79189158"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"}],"raw_author_name":"Iv\u00e1n Bravo","raw_affiliation_strings":["Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain"],"raw_orcid":"https://orcid.org/0000-0003-1589-5399","affiliations":[{"raw_affiliation_string":"Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","institution_ids":[]},{"raw_affiliation_string":"Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain","institution_ids":["https://openalex.org/I79189158"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048803040","display_name":"Agust\u00edn Lara\u2010S\u00e1nchez","orcid":"https://orcid.org/0000-0001-6547-4862","observed_orcids":["https://orcid.org/0000-0001-6547-4862"]},"institutions":[{"id":"https://openalex.org/I79189158","display_name":"University of Castilla-La Mancha","ror":"https://ror.org/05r78ng12","country_code":"ES","type":"education","lineage":["https://openalex.org/I79189158"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"}],"raw_author_name":"Agust\u00edn Lara-Sanchez","raw_affiliation_strings":["Facultad de Ciencias y Tecnolog\u00edas Qu\u00edmicas, Universidad de Castilla-La Mancha, 13005 Ciudad Real, Spain"],"raw_orcid":"https://orcid.org/0000-0001-6547-4862","affiliations":[{"raw_affiliation_string":"Facultad de Ciencias y Tecnolog\u00edas Qu\u00edmicas, Universidad de Castilla-La Mancha, 13005 Ciudad Real, Spain","institution_ids":["https://openalex.org/I79189158"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033819383","display_name":"Carlos Alonso\u2010Moreno","orcid":"https://orcid.org/0000-0002-7588-0781","observed_orcids":["https://orcid.org/0000-0002-7588-0781"]},"institutions":[{"id":"https://openalex.org/I79189158","display_name":"University of Castilla-La Mancha","ror":"https://ror.org/05r78ng12","country_code":"ES","type":"education","lineage":["https://openalex.org/I79189158"]}],"countries":["ES"],"is_corresponding":true,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Carlos Alonso-Moreno","raw_affiliation_strings":["Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain"],"raw_orcid":"https://orcid.org/0000-0002-7588-0781","affiliations":[{"raw_affiliation_string":"Centro Regional de Investigaciones Biom\u00e9dicas, Unidad NanoCRIB, 02008 Albacete, Spain","institution_ids":[]},{"raw_affiliation_string":"Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain","institution_ids":["https://openalex.org/I79189158"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074810713","display_name":"Alberto Oca\u00f1a","orcid":"https://orcid.org/0000-0002-1067-9630","observed_orcids":["https://orcid.org/0000-0002-1067-9630","https://orcid.org/0009-0007-2974-5662"]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210097846","display_name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/014v12a39","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210097846"]},{"id":"https://openalex.org/I4210155114","display_name":"Complejo Hospitalario Universitario de Albacete","ror":"https://ror.org/04a5hr295","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210141158","https://openalex.org/I4210155114"]},{"id":"https://openalex.org/I4210158561","display_name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","ror":"https://ror.org/04hya7017","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210158561"]}],"countries":["ES"],"is_corresponding":true,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Alberto Oca\u00f1a","raw_affiliation_strings":["Experimental Therapeutics Unit, Hospital cl\u00ednico San Carlos, IdISSC and CIBERONC, 28029 Madrid, Spain","Oncolog\u00eda Traslacional, Centro Regional de Investigaciones Biom\u00e9dicas, 02008 Albacete, Spain","Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Unit, Hospital cl\u00ednico San Carlos, IdISSC and CIBERONC, 28029 Madrid, Spain","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210097846","https://openalex.org/I4210158561"]},{"raw_affiliation_string":"Oncolog\u00eda Traslacional, Centro Regional de Investigaciones Biom\u00e9dicas, 02008 Albacete, Spain","institution_ids":[]},{"raw_affiliation_string":"Oncolog\u00eda Traslacional, Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain","institution_ids":["https://openalex.org/I4210155114"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5033819383","https://openalex.org/A5074810713"],"corresponding_institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210097846","https://openalex.org/I4210155114","https://openalex.org/I4210158561","https://openalex.org/I79189158"],"apc_list":{"value":1800,"currency":"CHF","value_usd":1901},"apc_paid":{"value":1800,"currency":"CHF","value_usd":1901},"fwci":2.5424,"has_fulltext":true,"cited_by_count":93,"citation_normalized_percentile":{"value":0.90841152,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"12","issue":"10","first_page":"986","last_page":"986"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.27000001072883606,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11686","display_name":"Dendrimers and Hyperbranched Polymers","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2507","display_name":"Polymers and Plastics"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-conjugated-nanoparticles","display_name":"antibody-conjugated nanoparticles","score":0.8109999895095825},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8920000195503235},{"id":"https://openalex.org/keywords/polymeric-nanoparticles","display_name":"polymeric nanoparticles","score":0.8569999933242798},{"id":"https://openalex.org/keywords/controlled-drug-release","display_name":"controlled drug release","score":0.7210000157356262},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8759999871253967},{"id":"https://openalex.org/keywords/her2-overexpression","display_name":"HER2 overexpression","score":0.9549999833106995},{"id":"https://openalex.org/keywords/brd2","display_name":"BRD2","score":0.5720000267028809},{"id":"https://openalex.org/keywords/brd4","display_name":"BRD4","score":0.8259999752044678},{"id":"https://openalex.org/keywords/bromodomain-inhibitors","display_name":"bromodomain inhibitors","score":0.7559999823570251},{"id":"https://openalex.org/keywords/proteasomal-degradation","display_name":"proteasomal degradation","score":0.8090000152587891},{"id":"https://openalex.org/keywords/nanoparticle-encapsulation","display_name":"nanoparticle encapsulation","score":0.5870000123977661},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.921999990940094}],"concepts":[{"id":"https://openalex.org/C74401373","wikidata":"https://www.wikidata.org/wiki/Q1829843","display_name":"Bromodomain","level":4,"score":0.6566442847251892},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5054292678833008},{"id":"https://openalex.org/C112613896","wikidata":"https://www.wikidata.org/wiki/Q898370","display_name":"Conjugated system","level":3,"score":0.5038053393363953},{"id":"https://openalex.org/C155672457","wikidata":"https://www.wikidata.org/wiki/Q61231","display_name":"Nanoparticle","level":2,"score":0.49350011348724365},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.48375391960144043},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.4780431389808655},{"id":"https://openalex.org/C28005876","wikidata":"https://www.wikidata.org/wiki/Q189814","display_name":"Endocytosis","level":3,"score":0.41965189576148987},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38068071007728577},{"id":"https://openalex.org/C171250308","wikidata":"https://www.wikidata.org/wiki/Q11468","display_name":"Nanotechnology","level":1,"score":0.3732128143310547},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.3570924997329712},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.34520423412323},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3267749845981598},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.2926393151283264},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.23158010840415955},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2035394012928009},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.1799103021621704},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1150326132774353},{"id":"https://openalex.org/C521977710","wikidata":"https://www.wikidata.org/wiki/Q81163","display_name":"Polymer","level":2,"score":0.11362305283546448},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.10263726115226746},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.09892383217811584},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.06847018003463745},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3390/pharmaceutics12100986","doi":"https://doi.org/10.3390/pharmaceutics12100986","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics12100986","pdf_url":"https://www.mdpi.com/1999-4923/12/10/986/pdf?version=1603097897","source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7589709","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7589709/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"Text"},{"id":"pmid:33086530","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33086530","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:11103c891af34522ac86b866ec31ff02","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/11103c891af34522ac86b866ec31ff02","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmaceutics, Vol 12, Iss 10, p 986 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3390/pharmaceutics12100986","doi":"https://doi.org/10.3390/pharmaceutics12100986","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics12100986","pdf_url":"https://www.mdpi.com/1999-4923/12/10/986/pdf?version=1603097897","source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1877989298","display_name":null,"funder_award_id":"CTQ2017-84131-R and CTQ2016-81797-REDC Programa Redes Consolider","funder_id":"https://openalex.org/F4320322930","funder_display_name":"Ministerio de Ciencia e Innovaci\u00f3n"},{"id":"https://openalex.org/G576905469","display_name":"Identificaci\u00f3n de vulnerabilidades en c\u00e1ncer de mama triple negativo: an\u00e1lisis de la heterogeneidad clonal de subpoblaciones tumorales","funder_award_id":"PI16/01121","funder_id":"https://openalex.org/F4320334923","funder_display_name":"Instituto de Salud Carlos III"},{"id":"https://openalex.org/G5885760961","display_name":null,"funder_award_id":"CTQ2016-81797-REDC","funder_id":"https://openalex.org/F4320322930","funder_display_name":"Ministerio de Ciencia e Innovaci\u00f3n"},{"id":"https://openalex.org/G5963771349","display_name":null,"funder_award_id":"CTQ2017-84131-R","funder_id":"https://openalex.org/F4320322930","funder_display_name":"Ministerio de Ciencia e Innovaci\u00f3n"},{"id":"https://openalex.org/G7943694199","display_name":null,"funder_award_id":"01319","funder_id":"https://openalex.org/F4320322930","funder_display_name":"Ministerio de Ciencia e Innovaci\u00f3n"}],"funders":[{"id":"https://openalex.org/F4320322930","display_name":"Ministerio de Ciencia e Innovaci\u00f3n","ror":null},{"id":"https://openalex.org/F4320324466","display_name":"Universidad de Castilla-La Mancha","ror":"https://ror.org/05r78ng12"},{"id":"https://openalex.org/F4320334923","display_name":"Instituto de Salud Carlos III","ror":"https://ror.org/00ca2c886"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3093071830.pdf","grobid_xml":"https://content.openalex.org/works/W3093071830.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W1110629363","https://openalex.org/W1565539350","https://openalex.org/W1972602765","https://openalex.org/W2045401050","https://openalex.org/W2079512206","https://openalex.org/W2081801534","https://openalex.org/W2151683271","https://openalex.org/W2163559554","https://openalex.org/W2344598639","https://openalex.org/W2409568753","https://openalex.org/W2597078857","https://openalex.org/W2732893177","https://openalex.org/W2761240402","https://openalex.org/W2787910603","https://openalex.org/W2806672448","https://openalex.org/W2885266495","https://openalex.org/W2890850288","https://openalex.org/W2902945052","https://openalex.org/W2908747386","https://openalex.org/W2909673413","https://openalex.org/W2912114516","https://openalex.org/W2935912602","https://openalex.org/W2944317821","https://openalex.org/W2946679128","https://openalex.org/W2970782214","https://openalex.org/W2970837975","https://openalex.org/W2982299031","https://openalex.org/W2989475496","https://openalex.org/W2996211630","https://openalex.org/W2996380129","https://openalex.org/W3000184977","https://openalex.org/W3005962215","https://openalex.org/W3011413773","https://openalex.org/W3011438376","https://openalex.org/W3043934334"],"related_works":["https://openalex.org/W7214608391","https://openalex.org/W4402333719","https://openalex.org/W4248980509","https://openalex.org/W7164751306","https://openalex.org/W4394755340","https://openalex.org/W3008371422","https://openalex.org/W4287958717","https://openalex.org/W7130699709","https://openalex.org/W3146169114","https://openalex.org/W4388976156"],"abstract_inverted_index":{"Bromo":[0],"and":[1,31,35,51,64,110,119,137],"extraterminal":[2],"domain":[3],"(BET)":[4],"inhibitors-PROteolysis":[5],"TArgeting":[6],"Chimera":[7],"(BETi-PROTAC)":[8],"is":[9],"a":[10,128],"new":[11],"family":[12],"of":[13,22,38,91,106,113,135],"compounds":[14],"that":[15,97],"induce":[16],"proteasomal":[17],"degradation":[18],"through":[19,40],"the":[20,23,70,77,89,114,123],"ubiquitination":[21],"tagged":[24],"to":[25,87,93],"BET":[26],"inhibitors":[27],"Bromodomain":[28],"proteins,":[29],"BRD2":[30],"BRD.":[32],"The":[33,81],"encapsulation":[34],"controlled":[36],"release":[37,120],"BET-PROTACs":[39],"their":[41,49],"vectorization":[42],"with":[43,85,117],"antibodies,":[44],"like":[45],"trastuzumab,":[46],"could":[47],"facilitate":[48],"pharmacokinetic":[50],"efficacy":[52],"profile.":[53],"Antibody":[54],"conjugated":[55,84],"nanoparticles":[56,82],"(ACNPs)":[57],"using":[58],"PROTACs":[59],"have":[60],"not":[61],"been":[62],"designed":[63],"evaluated.":[65],"In":[66],"this":[67],"pioneer":[68],"approach,":[69],"commercial":[71],"MZ1":[72,92],"PROTAC":[73],"was":[74],"encapsulated":[75],"into":[76],"FDA-approved":[78],"polymeric":[79],"nanoparticles.":[80],"were":[83,102],"trastuzumab":[86],"guide":[88],"delivery":[90],"breast":[94],"tumoral":[95],"cells":[96],"overexpress":[98],"HER2.":[99],"These":[100],"ACNPs":[101,126],"characterized":[103],"by":[104],"means":[105],"size,":[107],"polydispersity":[108],"index,":[109],"Z-potential.":[111],"Morphology":[112],"nanoparticles,":[115],"along":[116],"stability":[118],"studies,":[121],"completed":[122],"characterization.":[124],"MZ1-loaded":[125],"showed":[127],"significant":[129],"cytotoxic":[130],"effect":[131],"maintaining":[132],"its":[133,139],"mechanism":[134],"action":[136],"improving":[138],"therapeutic":[140],"properties.":[141]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3093071830","counts_by_year":[{"year":2026,"cited_by_count":14},{"year":2025,"cited_by_count":22},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":15},{"year":2022,"cited_by_count":22},{"year":2021,"cited_by_count":7}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2020-10-22T00:00:00"}
